Solid Biosciences Inc. SLDB

Rank #2282 · Nasdaq · $0.6B market cap

⚠ Going-concern flag — the auditor (PricewaterhouseCoopers LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

26.1

P/E

-4.9

P/B

4.83

ROE

-98.6%

Op. Margin

–%

Debt Ratio

41%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -4.9x, P/B 4.83x. Ranks in the top 77% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -98.6%. Ranks in the top 94% of the universe.

Safety ★★★★☆

Excellent

Debt ratio 41%. Ranks in the top 20% of the universe. Under 100% is generally considered a safe level.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2018	$0.0B	$-0.0B	$-0.0B	$-0.1B	–	-19
2019	$0.0B	$-0.1B	$-0.1B	$0.1B	–	12
2020	$0.0B	$-0.1B	$-0.1B	$0.1B	–	29
2021	$0.0B	$-0.1B	$-0.1B	$0.1B	–	30
2022	$0.0B	$-0.1B	$-0.1B	$0.2B	-649.1	12
2023	–	$-0.1B	$-0.1B	$0.2B	–	23
2024	–	$-0.1B	$-0.1B	$0.2B	–	18
2025	–	$-0.1B	$-0.1B	$0.1B	–	41

← See the full screener